Drugs / ZYDPLA1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02620592 Comparator | Oct 2014 → Oct 2015 | diabetes mellitus | Zydus Lifesciences Limited | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-06-09 | Zydus Lifesciences Limited | Zydus announces data presentations on ZYDPLA1 A once-weekly small molecule DPP-IV inhibitor for treating diabetes, at the ENDO conference in Chicago, Illinois, USA. zyduslife.com ↗ |
| 2013-10-23 | Zydus Lifesciences Limited | Zydus announces US FDA approval for initiating Phase I clinical trials of ZYDPLA1 - a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes zyduslife.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZYDPLA1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02620592 ↗ |
| Route | Oral | “The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.” NCT02620592 ↗ |